Risdiplam (formerly RG7916) is an investigational, oral small molecule SMN2-splicing modifier designed to help the survival motor neuron 2 (SMN2) gene produce more SMN protein. It is in development for the treatment of spinal muscular atrophy (SMA).
If you have a Hayes login, click here to view the full report on the Knowledge Center.